New study maps platelet patterns to prevent treatment mistakes in rare blood disorder
NCT ID NCT05876221
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 30 times
Summary
This study looked back at 223 adults with acquired thrombotic thrombocytopenic purpura (aTTP) who received the drug caplacizumab. Researchers wanted to understand how platelet counts change during treatment and identify patterns that might mislead doctors into giving too much or too little therapy. The goal is to help doctors better interpret platelet responses and improve patient care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Cologne
Cologne, Germany
Conditions
Explore the condition pages connected to this study.